Sensors,
Год журнала:
2023,
Номер
23(24), С. 9676 - 9676
Опубликована: Дек. 7, 2023
Immune
therapy
for
cancer
patients
is
a
new
and
promising
area
that
in
the
future
may
complement
traditional
chemotherapy.
The
cell
expansion
phase
critical
part
of
process
chain
to
produce
large
number
high-quality,
genetically
modified
immune
cells
from
an
initial
sample
patient.
Smart
sensors
augment
ability
control
monitoring
system
react
real-time
key
parameter
variations,
adapt
different
patient
profiles,
optimize
process.
aim
current
work
develop
calibrate
smart
their
deployment
real
bioreactor
platform,
with
adaptive
diverse
patient/donor
profiles.
A
set
contrasting
has
been
implemented
tested
on
automated
batch
runs,
which
incorporate
advanced
data-driven
machine
learning
statistical
techniques
detect
variations
disturbances
features.
Furthermore,
'consensus'
approach
applied
six
sensor
alerts
as
confidence
factor
helps
human
operator
identify
significant
events
require
attention.
Initial
results
show
can
effectively
model
track
data
generated
by
Aglaris
FACER
bioreactor,
anticipate
within
30
min
time
window,
mitigate
perturbations
order
performance
indicators
quantity
quality.
In
quantitative
terms
event
detection,
consensus
across
runs
demonstrated
good
stability:
AI-based
(Fuzzy
Weighted
Aggregation)
gave
88%
86%
consensus,
respectively,
whereas
statistically
based
(Stability
Detector
Bollinger)
25%
42%
average
all
being
65%.
reflect
theoretical
approaches.
Finally,
even
higher
stability,
ranging
57%
98%
80%.
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(11), С. 3202 - 3202
Опубликована: Май 29, 2024
Cancer
encompasses
various
elements
occurring
at
the
cellular
and
genetic
levels,
necessitating
an
immunotherapy
capable
of
efficiently
addressing
both
aspects.
T
cells
can
combat
cancer
by
specifically
recognizing
antigens
on
them.
This
innate
capability
has
been
used
to
develop
immunotherapies,
but
most
them
only
target
through
major
histocompatibility
complexes
(MHCs).
New
gene-editing
techniques
such
as
clustered
regularly
interspaced
short
palindromic
repeat
(CRISPR)-associated
protein
9
(CRISPR-cas9)
precisely
edit
DNA
sequences.
CRISPR-cas9
made
it
possible
generate
genetically
engineered
chimeric
antigen
receptors
(CARs)
that
overcome
problems
associated
with
old
immunotherapies.
In
receptor
(CAR-T)
cell
therapy,
patient's
are
isolated
modified
exhibit
synthetic
CAR(s).
CAR-T
treatment
shown
remarkably
positive
clinical
outcomes
in
cancers
types.
Nevertheless,
there
challenges
reduce
effectiveness
solid
tumors.
It
is
required
address
these
order
make
therapy
a
better
safer
option.
Combining
other
immunotherapies
multiple
outcomes.
Moreover,
recently
generated
Boolean
logic-gated
advanced
CARs
along
artificial
intelligence
expanded
its
potential
treat
tumors
addition
blood
cancers.
review
aims
describe
structure,
types,
methods
cells.
The
applications
hematological
malignancies
tumours
have
described
detail.
addition,
this
discussion
addressed
limitations
cells,
explored
strategies
mitigate
CAR-T-related
toxicities,
delved
into
future
perspectives.
Applied Sciences,
Год журнала:
2024,
Номер
14(3), С. 1303 - 1303
Опубликована: Фев. 5, 2024
Cell
and
gene
therapies
represent
promising
new
treatment
options
for
many
diseases,
but
also
face
challenges
clinical
translation
delivery.
Hospital-based
GMP
facilities
enable
rapid
bench-to-bedside
development
patient
access
require
significant
adaptation
to
implement
pharmaceutical
manufacturing
in
healthcare
infrastructures
constrained
by
space,
regulations,
resources.
This
article
reviews
key
considerations,
constraints,
solutions
establishing
hospital
advanced
therapy
medicinal
products
(ATMPs).
Technologies
like
process
analytical
technology
(PAT),
continuous
manufacturing,
artificial
intelligence
(AI)
can
aid
these
through
enhanced
monitoring,
control,
automation.
However,
quality
systems
tailored
product
rather
than
just
compliance,
substantial
investment
infrastructure,
equipment,
personnel,
multi-departmental
coordination,
remain
crucial
successful
ATMP
drive
from
research
impact.
PLOS Digital Health,
Год журнала:
2025,
Номер
4(1), С. e0000464 - e0000464
Опубликована: Янв. 9, 2025
Precision,
or
personalised
medicine
has
advanced
requirements
for
medical
data
management
systems
(MedDMSs).
MedDMS
precision
should
be
able
to
process
hundreds
of
parameters
from
multiple
sites,
adaptable
while
remaining
in
sync
at
locations,
real-time
syncing
analytics
and
compliant
with
international
privacy
legislation.
This
paper
describes
the
LogiqSuite
software
solution,
aimed
support
a
solution
patient
care
(LogiqCare),
research
(LogiqScience)
science
(LogiqAnalytics)
level.
is
certified
legislations.
evaluates
five
types
use
cases
medicine,
ranging
collection
algorithm
development
implementation
integration
real-world
data.
The
evaluated
seven
projects
prehospital
triage,
cardiovascular
disease,
pulmonology,
oncology.
P4O2
consortium
uses
as
an
electronic
case
report
form
(eCRF)
that
allows
long
covid
pulmonary
diseases.
In
acute
myeloid
leukaemia,
study
different
sources
were
integrated
facilitate
easy
descriptive
various
questions.
AIDPATH
project,
LogiqCare
used
data,
LogiqScience
pseudonymous
CAR-T
cell
production
cancer
treatment.
both
these
oncological
LogiqAnalytics
also
machine
learning
develop
new
prediction
models
clinical-decision
(CDS).
recording
CDS
U-Prevent
risk
Stroke
Triage
App
triage.
discussed
relation
other
solutions
privacy-by-design,
stewardship
medicine.
multi-centre
registrations
monitoring,
interdisciplinary
consortia,
design
/
artificial
intelligence
(AI)
algorithms,
updated
models,
therapy
production,
monitoring
using
tools.
application
supports
Frontiers in Immunology,
Год журнала:
2023,
Номер
14
Опубликована: Ноя. 27, 2023
Engineering
immune
cells
to
treat
hematological
malignancies
has
been
a
major
focus
of
research
since
the
first
resounding
successes
CAR-T-cell
therapies
in
B-ALL.
Several
diseases
can
now
be
treated
highly
therapy-refractory
or
relapsed
conditions.
Currently,
number
CD19-
BCMA-specific
are
approved
for
acute
lymphoblastic
leukemia
(ALL),
diffuse
large
B-cell
lymphoma
(DLBCL),
mantle
cell
(MCL),
multiple
myeloma
(MM),
and
follicular
(FL).
The
implementation
these
significantly
improved
patient
outcome
survival
even
cases
with
previously
very
poor
prognosis.
In
this
comprehensive
review,
we
present
current
state
research,
recent
innovations,
applications
therapy
selected
group
hematologic
malignancies.
We
on
B-
T-cell
malignancies,
including
entities
cutaneous
peripheral
(T-ALL,
PTCL,
CTCL),
myeloid
(AML),
chronic
(CML),
lymphocytic
(CLL),
classical
Hodgkin-Lymphoma
(HL),
Burkitt-Lymphoma
(BL),
hairy
(HCL),
Waldenström’s
macroglobulinemia
(WM).
While
heterogenous,
highlight
several
similarly
used
approaches
(combination
established
therapeutics,
target
depletion
healthy
cells),
targets
(CD30,
CD38,
TRBC1/2),
unique
features
that
require
individualized
approaches.
Furthermore,
limitations
individual
such
as
immunocompromising
tumor
microenvironment
(TME),
risk
on-target-off-tumor
effects,
differences
occurrence
adverse
events.
Finally,
an
outlook
into
novel
innovations
engineering
like
use
artificial
intelligence
future
role
CAR-T
regimens
everyday
clinical
practice.
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Фев. 11, 2024
Abstract
Introduction
Precision,
or
personalised
medicine
has
advanced
requirements
for
medical
data
management
systems
(MedDMSs).
MedDMS
precision
should
be
able
to
process
hundreds
of
parameters
from
multiple
sites,
adaptable
while
remaining
in
sync
at
locations,
real-time
syncing
analytics
and
compliant
with
international
privacy
legislation.
This
paper
describes
the
LogiqSuite
software
solution,
aimed
support
a
solution
patient
care
(LogiqCare),
research
(LogiqScience)
science
(LogiqAnalytics)
level.
is
certified
legislations.
Method
evaluates
five
types
use
cases
medicine,
ranging
collection
algorithm
development
implementation
integration
real-world
data.
The
evaluated
seven
projects
prehospital
triage,
cardiovascular
disease,
pulmonology,
oncology.
Results
P4O2
consortium
uses
as
an
electronic
case
report
form
(eCRF)
that
allows
long
covid
pulmonary
diseases.
In
acute
myeloid
leukaemia
study
different
sources
were
integrated
facilitate
easy
descriptive
various
questions.
AIDPATH
project,
LogiqCare
used
data,
LogiqScience
pseudonymous
CAR-T
cell
production
cancer
treatment.
both
these
oncological
LogiqAnalytics
also
machine
learning
develop
new
prediction
models
clinical-decision
(CDS).
recording
CDS
U-Prevent
risk
Stroke
Triage
App
triage.
Discussion
discussed
relation
other
solutions
privacy-by-design,
stewardship
medicine.
Conclusion
multi-centre
registrations
monitoring,
interdisciplinary
consortia,
design
/
artificial
intelligence
(AI)
algorithms,
updated
models,
therapy
production,
monitoring
using
tools.
application
supports
Journal of Translational Medicine,
Год журнала:
2024,
Номер
22(1)
Опубликована: Авг. 5, 2024
Asthma
poses
a
major
public
health
burden.
While
existing
asthma
drugs
manage
symptoms
for
many,
some
patients
remain
resistant.
The
lack
of
cure,
especially
severe
asthma,
compels
exploration
novel
therapies.
Cancer
immunotherapy
successes
with
CAR-T
cells
suggest
its
potential
treatment.
Researchers
are
exploring
various
approaches
allergic
diseases
including
membrane-bound
IgE,
IL-5,
PD-L2,
and
CTLA-4
Dectin-1
fungal
asthma.
NK
offer
several
advantages
over
T
CAR-based
immunotherapy.
They
key
benefits:
(1)
HLA
compatibility,
meaning
they
can
be
used
in
wider
range
without
the
need
matching
tissue
types.
(2)
Minimal
side
effects
(CRS
GVHD)
due
to
their
limited
persistence
cytokine
profile.
(3)
Scalability
"off-the-shelf"
production
from
sources.
Several
strategies
have
been
introduced
that
highlight
superiority
challenges
CAR-NK
cell
therapy
treatment
IL-10,
IFN-γ,
ADCC,
perforin-granzyme,
FASL,
KIR,
NCRs
(NKP46),
DAP,
DNAM-1,
TGF-β,
TNF-α,
CCL,
NKG2A,
TF,
EGFR.
Furthermore,
we
advocate
incorporating
AI
CAR
design
optimization
CRISPR-Cas9
gene
editing
technology
precise
manipulation
generate
highly
effective
constructs.
This
review
will
delve
into
evolution
designs,
explore
pre-clinical
clinical
studies
therapies
analyze
optimize
function,
conduct
comparative
analysis
respective
challenges,
finally
present
established
designs
promising
